ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded at ValuEngine

ValuEngine upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from a hold rating to a buy rating in a report issued on Tuesday, ValuEngine reports.

Several other equities analysts also recently commented on the stock. Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals from a hold rating to a buy rating and set a $26.00 price target on the stock in a report on Thursday, July 25th. Raymond James upped their price target on shares of ACADIA Pharmaceuticals from $40.00 to $43.00 and gave the company a strong-buy rating in a report on Friday, May 31st. Cantor Fitzgerald reiterated an overweight rating and set a $40.00 price target (up from $30.00) on shares of ACADIA Pharmaceuticals in a report on Tuesday, August 27th. Needham & Company LLC upped their price target on shares of ACADIA Pharmaceuticals from $34.00 to $60.00 and gave the company a buy rating in a report on Monday. Finally, Piper Jaffray Companies upped their price target on shares of ACADIA Pharmaceuticals from $35.00 to $56.00 and gave the company an overweight rating in a report on Monday. Five investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $43.31.

Shares of NASDAQ:ACAD opened at $39.14 on Tuesday. The company has a market capitalization of $5.61 billion, a price-to-earnings ratio of -20.18 and a beta of 2.75. ACADIA Pharmaceuticals has a 12 month low of $13.51 and a 12 month high of $43.98. The firm’s 50-day moving average is $28.11 and its 200 day moving average is $26.40. The company has a current ratio of 6.85, a quick ratio of 6.79 and a debt-to-equity ratio of 0.02.



ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.08. The company had revenue of $83.21 million for the quarter, compared to the consensus estimate of $72.50 million. ACADIA Pharmaceuticals had a negative net margin of 101.45% and a negative return on equity of 70.97%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.51) EPS. As a group, equities analysts forecast that ACADIA Pharmaceuticals will post -1.77 EPS for the current fiscal year.

In other ACADIA Pharmaceuticals news, Director James M. Daly sold 30,000 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $37.80, for a total value of $1,134,000.00. Following the completion of the sale, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $1,134,000. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric Alejandro Miller sold 28,467 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $39.49, for a total transaction of $1,124,161.83. The disclosure for this sale can be found here. Over the last three months, insiders sold 63,112 shares of company stock valued at $2,449,443. 29.40% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in ACAD. Geode Capital Management LLC boosted its position in ACADIA Pharmaceuticals by 16.7% in the 4th quarter. Geode Capital Management LLC now owns 1,244,939 shares of the biopharmaceutical company’s stock valued at $20,130,000 after buying an additional 177,701 shares during the period. Bank of Montreal Can boosted its position in ACADIA Pharmaceuticals by 289.9% in the 1st quarter. Bank of Montreal Can now owns 53,038 shares of the biopharmaceutical company’s stock valued at $1,424,000 after buying an additional 39,435 shares during the period. Rhumbline Advisers boosted its position in ACADIA Pharmaceuticals by 13.0% in the 1st quarter. Rhumbline Advisers now owns 150,068 shares of the biopharmaceutical company’s stock valued at $4,029,000 after buying an additional 17,252 shares during the period. American International Group Inc. boosted its position in ACADIA Pharmaceuticals by 11.4% in the 1st quarter. American International Group Inc. now owns 72,216 shares of the biopharmaceutical company’s stock valued at $1,939,000 after buying an additional 7,418 shares during the period. Finally, Parametrica Management Ltd purchased a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter worth approximately $219,000. 97.38% of the stock is owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Featured Story: SEC Filing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.